

## Regimen Reference Order – LEUK – AL4 (Continuation)

ARIA: LEUK - [AL4 (Continuation)]

**Planned Course:** 1 cycle = 21 days  
*Repeat Continuation Therapy until the total duration of therapy is 2 years from the date of Complete Remission*

**Indication for Use:** Acute Lymphoblastic Leukemia

**CVAD:** Preferred (VESICANT INVOLVED)

**Proceed with treatment if:**

**Cycle 1 Day 1**

- **ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$**
- **AST less than 8 times the upper limit of normal**
- **Direct bilirubin less than  $25 \mu\text{mol/L}$**

**Cycle 2 and Onwards Day 1**

- **ANC equal to or greater than  $0.5 \times 10^9/L$  AND Platelets equal to or greater than  $75 \times 10^9/L$**
- **AST less than 8 times the upper limit of normal**
- **Direct bilirubin less than  $25 \mu\text{mol/L}$**
- ❖ **Contact Leukemia/BMT (L/BMT) Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

| Drug           | Dose | CCMB Administration Guideline |
|----------------|------|-------------------------------|
| Not Applicable |      |                               |

#### Treatment Regimen – LEUK – AL4 (Continuation)

Establish primary solution 500 mL of: normal saline

| Drug           | Dose  | CCMB Administration Guideline  |
|----------------|---|--|
| dexamethasone  | 6 mg/m <sup>2</sup> /day<br>(Round to nearest 2 mg) | Orally divided twice a day with food on <b>Days 1 to 5</b><br><b>(Self-administered at home)</b>   |
| vinCRISStine   | 2 mg<br>(Standard dose)                             | IV in normal saline 25 mL over 2 minutes on <b>Day 1</b>   |
| mercaptopurine | 50 mg/m <sup>2</sup><br>(Round to nearest 25 mg)    | Orally once daily on an empty stomach <b>on Days 1 to 14</b><br>Do not take with milk or milk-based products<br><b>(Self-administered at home)</b> |
| methotrexate   | 60 mg/m <sup>2</sup>                                | Orally once weekly on <b>Days 2, 9 and 16</b> . Take on an empty stomach<br><b>(Self-administered at home)</b>                                     |

Patients will receive Triple Intrathecal Therapy every 18 weeks while receiving continuation therapy (Patient is placed on support regimen – LEUK – [AL4 (IT)] beginning with CNS phase which occurs every 126 days = 18 weeks). Intrathecal is given at the start of treatment cycles where possible. Refer to Appendix A

mercaptopurine (Purinethol®) available dosage strength: 50 mg tablets

Classification: Cytotoxic, Hazardous

Methotrexate available dosage strength: 2.5 mg tablets

Classification: Cytotoxic, Hazardous

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

AL4 (Continuation)

Day 1

- CBC and biochemistry as per Physician Orders

### Recommended Support Medications

| Drug                             | Dose      | CCMB Administration Guideline                    |
|----------------------------------|-----------|--|
| sulfamethoxazole-trimethoprim DS | 800/160mg | Orally twice daily on Saturdays and Sundays only |

## DISCHARGE INSTRUCTIONS

- If nausea or mucositis develops, instruct patient to contact their L/BMT physician
- sulfamethoxazole-trimethoprim should not be administered on intrathecal therapy days due to potential drug interaction
- mercaptopurine should not be taken at the same time as milk or milk-based products. Cow's milk in particular, contains high concentrations of xanthine oxidase which inactivates mercaptopurine
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

## ADDITIONAL INFORMATION

- Intrathecal therapy is part of this regimen and is given every 18 weeks. See APPENDIX A AL4 (IT)
- Dose adjustments are made to methotrexate and mercaptopurine to achieve a desired nadir ANC of  $0.5 \times 10^9/L$  to  $0.75 \times 10^9/L$  and platelets of  $75 \times 10^9/L$  to  $100 \times 10^9/L$
- Treatment may be delayed if patient is experiencing moderate or severe mucositis
- If patient has recurrent mouth sores, they may be evaluated for HSV and considered for valacyclovir prophylaxis

## APPENDIX A

## LEUK – AL4 (IT)

**Planned course: Every 18 weeks from the beginning of CNS Phase. Continue until the completion of AL4 (Continuation)**

***Proceed with treatment if:***

- ***ANC equal to or greater than  $0.5 \times 10^9/L$  AND Platelets equal to or greater than  $50 \times 10^9/L$***
- ❖ **Contact L/BMT Physician if parameters not met**

| Drug and Dose   | CCMB Administration Guideline  |
|---|--|
| <b>Every 18 weeks (Starting with beginning of CNS phase)</b>  |  |
| <b><u>Triple Intrathecal:</u></b><br>methotrexate 12 mg<br>cytarabine 40 mg<br>hydrocortisone 50 mg | Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic |

**IT is ordered as a separate cyclical Support regimen LEUK – [AL4 (IT)]**